WO2006030303A8 - Oral extended release dosage form comprising a high dose biguanide and a low dose sulfonylurea - Google Patents

Oral extended release dosage form comprising a high dose biguanide and a low dose sulfonylurea

Info

Publication number
WO2006030303A8
WO2006030303A8 PCT/IB2005/002753 IB2005002753W WO2006030303A8 WO 2006030303 A8 WO2006030303 A8 WO 2006030303A8 IB 2005002753 W IB2005002753 W IB 2005002753W WO 2006030303 A8 WO2006030303 A8 WO 2006030303A8
Authority
WO
WIPO (PCT)
Prior art keywords
biguanide
sulfonylurea
dose
extended release
dosage form
Prior art date
Application number
PCT/IB2005/002753
Other languages
French (fr)
Other versions
WO2006030303A1 (en
Inventor
Amit Kumar Kesarwani
Manish Chawla
Rajeev Singh Raghuvanshi
Ashok Kumar Rampal
Original Assignee
Ranbaxy Lab Ltd
Amit Kumar Kesarwani
Manish Chawla
Rajeev Singh Raghuvanshi
Ashok Kumar Rampal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd, Amit Kumar Kesarwani, Manish Chawla, Rajeev Singh Raghuvanshi, Ashok Kumar Rampal filed Critical Ranbaxy Lab Ltd
Publication of WO2006030303A1 publication Critical patent/WO2006030303A1/en
Publication of WO2006030303A8 publication Critical patent/WO2006030303A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to orally administered extended release pharmaceutical compositions that include a combination of: a/ a highly water-soluble, high dose biguanide in an extend release form and b/ a water-insoluble low dose sulfonylurea in an extend release form.
PCT/IB2005/002753 2004-09-17 2005-09-16 Oral extended release dosage form comprising a high dose biguanide and a low dose sulfonylurea WO2006030303A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1769DE2004 2004-09-17
IN1769/DEL/2004 2004-09-17

Publications (2)

Publication Number Publication Date
WO2006030303A1 WO2006030303A1 (en) 2006-03-23
WO2006030303A8 true WO2006030303A8 (en) 2006-07-06

Family

ID=35432385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002753 WO2006030303A1 (en) 2004-09-17 2005-09-16 Oral extended release dosage form comprising a high dose biguanide and a low dose sulfonylurea

Country Status (1)

Country Link
WO (1) WO2006030303A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS8660A (en) * 2007-07-02 2009-01-03 Actavis Group Ptc Ehf. Glycoside pharmaceutical composition
WO2014154640A1 (en) * 2013-03-25 2014-10-02 Sanovel Ilac Sanayi Ve Ticaret A.S. Controlled-release formulations comprising metformin and gliclazide
IT201800011119A1 (en) * 2018-12-14 2020-06-14 Dpl Pharma S P A SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR THE CHRONOTROPIC ADMINISTRATION OF SITAGLIPTIN

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration

Also Published As

Publication number Publication date
WO2006030303A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2005025541A3 (en) Dry powder composition comprising a benzodiazepine for pulmonary inhalation
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
WO2004050058A3 (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2007002597A3 (en) Modified-release formulations of a bupropion salt
WO2015120110A3 (en) Novel pharmaceutical formulations
WO2006056711A3 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
WO2006124047A3 (en) Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2004074266A8 (en) Hiv inhibiting 1,2,4-triazines
IL184065A (en) Tetrahydroquinoline analogues, uses thereof in the preparation of medicaments and pharmaceutical compositions comprising same
WO2004066910A8 (en) Controlled release modifying complex and pharmaceutical compositions thereof
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2010066749A3 (en) Ulipristal acetate tablets
WO2008035020A3 (en) Galenic form for the trans-mucosal delivery of active ingredients
WO2005084648A8 (en) Pharmaceutical compositions comprising candesartan cilexetil
HK1089950A1 (en) Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
PL382307A1 (en) The manner of preparation of pharmaceutical composition in form of quick dispersive dose and stable, oral, quickly dispersive form of a dosage
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
ATE499939T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLIBANSERIN POLYMORPHO A
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
WO2009068708A8 (en) Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof
WO2008003050A3 (en) Gallium nitrate formulations
IL207928A (en) Pharmaceutical composition comprising a methotrexate (mtx) active agent and a 2,2-anhydropyrimidine adjuvant for reducing mtx toxicity and use thereof in the preparation of medicaments
WO2005065639A3 (en) Novel pharmaceutical compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase